AMINOSYN 7% W/ ELECTROLYTES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN 7% W/ ELECTROLYTES (AMINOSYN 7% W/ ELECTROLYTES).
Amino acids are the building blocks for protein synthesis in the body. This solution provides essential and non-essential amino acids to maintain nitrogen balance and support tissue repair and growth when oral intake is inadequate.
| Metabolism | Amino acids undergo distribution and are primarily metabolized through deamination, transamination, and decarboxylation reactions in the liver and other tissues. The carbon skeletons are used for energy production or gluconeogenesis; the nitrogen is converted to urea in the liver and excreted renally. |
| Excretion | Primarily renal. Amino acids are deaminated, and nitrogen is excreted as urea in urine. Biliary/fecal excretion is negligible. Almost 100% of infused amino acids are either metabolized or excreted as urea and other nitrogenous wastes. |
| Half-life | Terminal elimination half-life for the constituent amino acids ranges from 0.5 to 4 hours, depending on the specific amino acid and metabolic state. Clinically, infusion rate should be adjusted to avoid accumulation in renal impairment. |
| Protein binding | Minimal (<5%) for most amino acids; not significantly bound to plasma proteins. Some amino acids (e.g., tryptophan) show moderate albumin binding (~30%), but overall protein binding is negligible. |
| Volume of Distribution | Approximately 0.5-0.8 L/kg, reflecting distribution into total body water. Larger Vd in edematous states; lower in dehydration. Confined to extracellular fluid initially, then intracellular uptake occurs. |
| Bioavailability | Not applicable for oral route. Intravenous bioavailability is 100% by definition. |
| Onset of Action | Intravenous: Onset of nitrogen balance improvement occurs within 24-48 hours of continuous infusion. Serum amino acid levels rise promptly upon initiation. |
| Duration of Action | Duration of effect (nitrogen balance) persists as long as infusion continues; metabolic effects last for hours post-infusion decline in serum levels. Clinical duration is dependent on continuous administration. |
Intravenous infusion at 1-1.5 g amino acids/kg/day. Typical adult dose: 500 mL of 7% solution (35 g amino acids) infused over 8-12 hours, repeated daily as per nitrogen requirements.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <50 mL/min: Reduce to 0.5-0.8 g amino acids/kg/day and monitor BUN. GFR <15 mL/min: Avoid or use with caution, typically not recommended unless on renal replacement therapy. |
| Liver impairment | Child-Pugh Class B or C: Reduce dose by 50% or use branched-chain amino acid-enriched solutions. Avoid in severe hepatic encephalopathy. |
| Pediatric use | 1-2.5 g amino acids/kg/day by continuous IV infusion. For infants, start at 1 g/kg/day and increase gradually; confirm with total parenteral nutrition guidelines. |
| Geriatric use | Initiate at lower end of adult range (1 g/kg/day) and adjust based on renal function and nutritional status. Monitor fluid balance due to risk of volume overload. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN 7% W/ ELECTROLYTES (AMINOSYN 7% W/ ELECTROLYTES).
| Breastfeeding | AminoSyn 7% w/ Electrolytes is compatible with breastfeeding. Exogenous amino acids given intravenously are not known to pose risk to nursing infant. M/P ratio not established; maternal plasma amino acid levels transiently increase but breast milk levels are negligible due to rapid metabolism. Continue breastfeeding while monitoring infant for metabolic acidosis if infant has inborn errors of metabolism (e.g., urea cycle disorders). |
| Teratogenic Risk | Parenteral amino acid solutions are considered essential in pregnancy for maternal and fetal nutrition when oral intake is inadequate. No known teratogenic effects have been reported with standard clinical use. FDA Category C: animal reproduction studies not conducted; potential benefits may warrant use despite potential risks. No evidence of fetal harm in first trimester; continuous IV amino acids may cause metabolic disturbances in fetus (e.g., acidosis, hyperammonemia) if maternal levels are excessive. |
■ FDA Black Box Warning
This formulation contains aluminum, which may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are at higher risk because their kidneys are immature, and they require large amounts of calcium/phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including preterm neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. In neonates, aluminum toxicity may be manifested as impaired neurologic development.
| Serious Effects |
["Hypersensitivity to any component","Severe electrolyte or acid-base imbalance","Anuria or severe renal impairment without dialysis","Inborn errors of amino acid metabolism (e.g., phenylketonuria)","Severe hepatic failure with encephalopathy","Hepatic coma"]
| Precautions | ["Monitor serum electrolytes, fluid balance, acid-base status, and liver function regularly.","Risk of hyperglycemia or hypoglycemia; adjust dextrose accordingly.","Do not administer if solution is discolored or contains particulate matter.","Use with caution in patients with renal impairment, hepatic disease, or metabolic disorders.","May cause venous irritation; use central line for long-term therapy."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (especially potassium, sodium, chloride, magnesium, phosphorus) and acid-base status. Assess blood urea nitrogen and creatinine. Monitor for signs of fluid overload (edema, pulmonary congestion) and hyperglycemia. Fetal monitoring: growth scans, biophysical profile, and amniotic fluid index if used for prolonged parenteral nutrition. Check maternal ammonia levels if hepatic impairment present. |
| Fertility Effects | No direct adverse effects on fertility. Restoration of nutritional status in malnourished women may improve ovulation and fertility. No human studies specifically evaluating fertility. In animal studies, no impairment of fertility observed at clinically relevant doses. |
| Food/Dietary | No direct food interactions since administered intravenously. However, oral intake is typically restricted or guided based on underlying condition. Monitor for electrolyte imbalances if concurrent enteral nutrition or oral supplements are used. |
| Clinical Pearls | Aminosyn 7% w/ Electrolytes is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes and acid-base balance frequently due to risk of hyperchloremic metabolic acidosis from high chloride content. Adjust infusion rate based on metabolic tolerance and renal function. Contains 50 mEq/L acetate and 40 mEq/L chloride; use with caution in patients with renal impairment or hepatic encephalopathy. |
| Patient Advice | This medication provides nutrition through a vein; you will be monitored regularly for side effects. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · Tell your healthcare provider if you experience nausea, vomiting, weakness, or confusion. · You may need blood tests to check your kidney and liver function, blood sugar, and electrolyte levels. · Do not stop or change the infusion rate without consulting your healthcare provider. |